Abstract
The ErbB family of receptor tyrosine kinases comprises of epidermal growth factor (EGF) receptor (HER1/ErbB1), HER2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Interaction of ErbB receptors with a ligand leads to formation of higher-order aggregates which may form signaling platforms in the plasma membrane. ErbB2 is the only receptor which doesn’t need a ligand for activation. Various molecules have been developed which block ErbB signaling by either generating antibodies against the extracellular domain of the EGF receptor or directly inhibiting ErbB1/EGF signaling. The relevance of the ErbB family of receptors as actionable targets in renal cell carcinoma is a topic of debate. Some of the recently developed drugs that are discussed in this chapter and have been studied in renal cell carcinoma are cetuximab, panitumumab, gefitinib, erlotinib, and lapatinib. These agents have failed to demonstrate consistent clinical benefit in patients with advanced renal cell carcinoma and are currently not considered standard treatment in this disease.
Original language | English (US) |
---|---|
Publisher | Springer New York |
Number of pages | 18 |
ISBN (Electronic) | 9781493916221 |
ISBN (Print) | 9781493916214 |
DOIs | |
State | Published - Jan 1 2015 |
Keywords
- ErbB
- Renal cell carcinoma
- Resistance
- Signaling
- Targeted therapy
ASJC Scopus subject areas
- General Medicine